GlassScriptPhysician profile
Steven T Ehrreich
NPI 1780651893
$58,542.06
in general payments reported to CMS, 2019-2025
54 companies · $17K in 2025
The $17K reported for 2025 was more than what 99% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,141 · 2020: $1,214 · 2021: $2,750 · 2022: $16K · 2023: $9,416 · 2024: $8,143 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $9,402 · Honoraria: $4,000 · Travel and Lodging: $2,533.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,738.00 |
| Food and Beverage | $9,401.88 |
| Honoraria | $4,000.00 |
| Travel and Lodging | $2,532.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $32,121.84 | 2022-2025 | Epidiolex |
| Catalyst Pharmaceuticals, INC. | $6,179.32 | 2023-2025 | Fycompa |
| Immedica Pharma US, INC. | $4,055.86 | 2022-2024 | |
| Neuropace, INC. | $3,420.85 | 2019-2025 | |
| Zogenix INC. | $1,669.99 | 2020-2021 | |
| Ucb, INC. | $1,664.69 | 2019-2025 | Fintepla, Briviact, Nayzilam |
| Livanova USA, INC. | $1,228.06 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Neurelis, INC. | $1,068.16 | 2021-2025 | Valtoco |
| Greenwich Biosciences, INC. | $837.61 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $545.67 | 2019-2025 | Koselugo |
| Ipsen Biopharmaceuticals, INC | $470.18 | 2019-2025 | Dysport |
| Ptc Therapeutics, INC. | $457.27 | 2019-2024 | Emflaza |
| Eisai INC. | $453.41 | 2019-2023 | |
| Supernus Pharmaceuticals, INC. | $398.99 | 2019-2025 | Qelbree, Oxtellar Xr |
| Aucta Pharmaceuticals, INC. | $328.76 | 2024-2025 | Motpoly Xr |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Ehrreich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.